NIH Chief to Step Down

After six years and nearly $5 billion in budgetary increases, Harold Varmus announced Oct. 7 that he is leaving the National Institutes of Health to head the Memorial Sloan-Kettering Cancer Center in New York. When Varmus took on the NIH directorship in 1993, the agency posted a budget of $11 billion. The budget for fiscal year 1999 soared to $15.6 billion. Scientists on the NIH campus also have praised Varmus for reinvigorating what was once a flagging institution.1 "Harold Varmus has done ever

Written byPaul Smaglik
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

After six years and nearly $5 billion in budgetary increases, Harold Varmus announced Oct. 7 that he is leaving the National Institutes of Health to head the Memorial Sloan-Kettering Cancer Center in New York. When Varmus took on the NIH directorship in 1993, the agency posted a budget of $11 billion. The budget for fiscal year 1999 soared to $15.6 billion. Scientists on the NIH campus also have praised Varmus for reinvigorating what was once a flagging institution.1

"Harold Varmus has done everything well--demanding the best science, rejuvenating the NIH leadership, inspiring confidence from the Congress," notes Francis Collins, director of the National Human Genome Research Institute, which has grown under Varmus' leadership. During his tenure, he floated a variety of trial balloons, some of which deflated, some of which soared, and some of which seem ready for launch. His proposed NIH graduate school and a revamped organizational structure never ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies